Correlation between Anti-Müllerian Hormone and Polycystic Ovary Syndrome

doi:10.12280/gjfckx.20220217

Abstract

Abstract:

Anti-Müllerian hormone (AMH) is significantly elevated in patients with polycystic ovary syndrome (PCOS), which may be related to the primitive follicular development disorder of PCOS. The pathogenesis of PCOS is still unknown, and AMH may be an important pathogenic factor that plays a regulatory role through neuroendocrine mechanism and autophagy mechanism. In addition, the genetic changes of AMH and its receptor are also involved, which constitutes the epigenetic mechanism of PCOS. AMH can also be used as a biochemical index for the diagnosis of PCOS, the cutoff can be adjusted according to age and type. AMH is also correlated with the adverse pregnancy outcomes of PCOS, which can be used as a predictor of preterm birth. This paper reviews the research progress of AMH in the pathogenesis, diagnosis and impact on pregnancy outcomes of PCOS, so as to provide theoretical basis for the clinical work of obstetrics and gynecology.

Key words: Anti-mullerian hormone, Polycystic ovary syndrome, Ovarian follicle, Autophagy, Diagnosis, Pregnancy outcome

ZHAO Qian, ZHOU Shu. Correlation between Anti-Müllerian Hormone and Polycystic Ovary Syndrome[J]. Journal of International Obstetrics and Gynecology, 2022, 49(6): 659-663.

References 36

[1]	Monsivais D, Matzuk MM, Pangas SA. The TGF-β Family in the Reproductive Tract[J]. Cold Spring Harb Perspect Biol, 2017, 9(10):a022251. doi: 10.1101/cshperspect.a022251. doi: 10.1101/cshperspect.a022251
[2]	Pankhurst MW. A putative role for anti-Müllerian hormone (AMH) in optimising ovarian reserve expenditure[J]. J Endocrinol, 2017, 233(1):R1-R13. doi: 10.1530/JOE-16-0522. doi: 10.1530/JOE-16-0522
[3]	Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection[J]. Mol Hum Reprod, 2013, 19(8):519-527. doi: 10.1093/molehr/gat024. doi: 10.1093/molehr/gat024 pmid: 23562944
[4]	Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women[J]. Hum Reprod Update, 2014, 20(3):370-385. doi: 10.1093/humupd/dmt062. doi: 10.1093/humupd/dmt062 pmid: 24430863
[5]	Sahmay S, Atakul N, Aydogan B, et al. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome[J]. Acta Obstet Gynecol Scand, 2013, 92(12):1369-1374. doi: 10.1111/aogs.12247. doi: 10.1111/aogs.12247
[6]	Abbara A, Eng PC, Phylactou M, et al. Anti-Müllerian hormone (AMH) in the Diagnosis of Menstrual Disturbance Due to Polycystic Ovarian Syndrome[J]. Front Endocrinol (Lausanne), 2019, 10:656. doi: 10.3389/fendo.2019.00656. doi: 10.3389/fendo.2019.00656
[7]	Hu KL, Liu FT, Xu H, et al. High antimüllerian hormone levels are associated with preterm delivery in patients with polycystic ovary syndrome[J]. Fertil Steril, 2020, 113(2):444-452.e1. doi: 10.1016/j.fertnstert.2019.09.039. doi: 10.1016/j.fertnstert.2019.09.039
[8]	Du J, Ruan X, Jin F, et al. Abnormalities of early folliculogenesis and serum anti-Müllerian hormone in chinese patients with polycystic ovary syndrome[J]. J Ovarian Res, 2021, 14(1):36. doi: 10.1186/s13048-021-00786-0. doi: 10.1186/s13048-021-00786-0 pmid: 33602276
[9]	Sir-Petermann T, Codner E, Maliqueo M, et al. Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2006, 91(8):3105-3109. doi: 10.1210/jc.2005-2693. doi: 10.1210/jc.2005-2693
[10]	Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis[J]. Nat Rev Endocrinol, 2011, 7(4):219-231. doi: 10.1038/nrendo.2010.217. doi: 10.1038/nrendo.2010.217 pmid: 21263450
[11]	Josso N, Picard JY. Genetics of anti-Müllerian hormone and its signaling pathway[J]. Best Pract Res Clin Endocrinol Metab, 2022, 36(1):101634. doi: 10.1016/j.beem.2022.101634. doi: 10.1016/j.beem.2022.101634
[12]	Cimino I, Casoni F, Liu X, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion[J]. Nat Commun, 2016, 7:10055. doi: 10.1038/ncomms10055. doi: 10.1038/ncomms10055 pmid: 26753790
[13]	Silva MS, Prescott M, Campbell RE. Ontogeny and reversal of brain circuit abnormalities in a preclinical model of PCOS[J]. JCI Insight, 2018, 3(7):e99405. doi: 10.1172/jci.insight.99405. doi: 10.1172/jci.insight.99405
[14]	Moore AM, Campbell RE. Polycystic ovary syndrome: Understanding the role of the brain[J]. Front Neuroendocrinol, 2017, 46:1-14. doi: 10.1016/j.yfrne.2017.05.002. doi: 10.1016/j.yfrne.2017.05.002
[15]	Tata B, Mimouni N, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood[J]. Nat Med, 2018, 24(6):834-846. doi: 10.1038/s41591-018-0035-5. doi: 10.1038/s41591-018-0035-5 pmid: 29760445
[16]	Kumariya S, Ubba V, Jha RK, et al. Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective[J]. Autophagy, 2021, 17(10):2706-2733. doi: 10.1080/15548627.2021.1938914. doi: 10.1080/15548627.2021.1938914
[17]	李小雪, 王桂泉, 朱琴玲, 等. 多囊卵巢综合征患者颗粒细胞自噬的发生及影响因素[J]. 中华生殖与避孕杂志, 2018, 38(7):531-535. doi: 10.3760/cma.j.issn.2096-2916.2018.07.002. doi: 10.3760/cma.j.issn.2096-2916.2018.07.002
[18]	Sonigo C, Beau I, Grynberg M, et al. AMH prevents primordial ovarian follicle loss and fertility alteration in cyclophosphamide-treated mice[J]. FASEB J, 2019, 33(1):1278-1287. doi: 10.1096/fj.201801089R. doi: 10.1096/fj.201801089R pmid: 30113879
[19]	Gorsic LK, Dapas M, Legro RS, et al. Functional Genetic Variation in the Anti-Müllerian Hormone Pathway in Women With Polycystic Ovary Syndrome[J]. J Clin Endocrinol Metab, 2019, 104(7):2855-2874. doi: 10.1210/jc.2018-02178. doi: 10.1210/jc.2018-02178 pmid: 30786001
[20]	Zhong X, Jin F, Huang C, et al. DNA methylation of AMHRII and INSR gene is associated with the pathogenesis of Polycystic Ovary Syndrome (PCOS)[J]. Technol Health Care, 2021, 29(S1):11-25. doi: 10.3233/THC-218002. doi: 10.3233/THC-218002 pmid: 33682741
[21]	Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J]. Clin Endocrinol (Oxf), 2018, 89(3):251-268. doi: 10.1111/cen.13795. doi: 10.1111/cen.13795
[22]	Ran Y, Yi Q, Li C. The Relationship of Anti-Mullerian Hormone in Polycystic Ovary Syndrome Patients with Different Subgroups[J]. Diabetes Metab Syndr Obes, 2021, 14:1419-1424. doi: 10.2147/DMSO.S299558. doi: 10.2147/DMSO.S299558
[23]	Dietz de Loos A, Hund M, Buck K, et al. Antimüllerian hormone to determine polycystic ovarian morphology[J]. Fertil Steril, 2021, 116(4):1149-1157. doi: 10.1016/j.fertnstert.2021.05.094. doi: 10.1016/j.fertnstert.2021.05.094 pmid: 34579824
[24]	Lie Fong S, Laven J, Duhamel A, et al. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis[J]. Hum Reprod, 2017, 32(8):1723-1731. doi: 10.1093/humrep/dex226. doi: 10.1093/humrep/dex226
[25]	Sahmay S, Oncul M, Mathyk B, et al. Age-specific serum AMH (Antimullerien Hormone) levels in women with and without polycystic ovary syndrome[J]. Maturitas, 2017, 100:159. doi:10.1016/j.maturitas.2017.03.144. doi: 10.1016/j.maturitas.2017.03.144
[26]	Ramezani Tehrani F, Rahmati M, Mahboobifard F, et al. Age-specific cut-off levels of anti-Müllerian hormone can be used as diagnostic markers for polycystic ovary syndrome[J]. Reprod Biol Endocrinol, 2021, 19(1):76. doi: 10.1186/s12958-021-00755-8. doi: 10.1186/s12958-021-00755-8
[27]	Ozay AC, Emekcı Ozay O, Gulekli B. Comparison of Anti-müllerian Hormone (AMH) and Hormonal Assays for Phenotypic Classification of Polycystic Ovary Syndrome[J]. Ginekol Pol, 2020, 91(11):661-667. doi: 10.5603/GP.a2020.0122. doi: 10.5603/GP.a2020.0122 pmid: 33301159
[28]	Dewailly D. Toward a universal serum antimüllerian hormone threshold as a surrogate for polycystic ovarian morphology on ultrasound: the story is not over[J]. Fertil Steril, 2021, 116(4):1158-1159. doi: 10.1016/j.fertnstert.2021.08.005. doi: 10.1016/j.fertnstert.2021.08.005 pmid: 34481641
[29]	李轶, 李瑞岐, 欧颂邦, 等. 高雄激素和非高雄激素型多囊卵巢综合征患者血清抗苗勒管激素分泌特点及诊断效能比较[J]. 实用妇产科杂志, 2014, 30(2):111-115.
[30]	Bahri Khomami M, Boyle JA, Tay CT, et al. Polycystic ovary syndrome and adverse pregnancy outcomes: Current state of knowledge, challenges and potential implications for practice[J]. Clin Endocrinol (Oxf), 2018, 88(6):761-769. doi: 10.1111/cen.13579. doi: 10.1111/cen.13579
[31]	Lyttle Schumacher BM, Jukic A, Steiner AZ. Antimüllerian hormone as a risk factor for miscarriage in naturally conceived pregnancies[J]. Fertil Steril, 2018, 109(6):1065-1071.e1. doi: 10.1016/j.fertnstert.2018.01.039. doi: S0015-0282(18)30065-7 pmid: 29871793
[32]	Liu X, Han Y, Wang X, et al. Serum anti-Müllerian hormone levels are associated with early miscarriage in the IVF/ICSI fresh cycle[J]. BMC Pregnancy Childbirth, 2022, 22(1):279. doi: 10.1186/s12884-022-04591-5. doi: 10.1186/s12884-022-04591-5
[33]	康佳. 小鼠Müllerian管发育的分子机制研究[D]. 北京: 中国医学科学院北京协和医学院, 2020.
[34]	Kim SM, Kim YO, Lee MK, et al. Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria[J]. Oncol Lett, 2019, 17(1):532-538. doi: 10.3892/ol.2018.9565. doi: 10.3892/ol.2018.9565 pmid: 30655798
[35]	Hsu JY, James KE, Bormann CL, et al. Müllerian-Inhibiting Substance/Anti-Müllerian Hormone as a Predictor of Preterm Birth in Polycystic Ovary Syndrome[J]. J Clin Endocrinol Metab, 2018, 103(11):4187-4196. doi: 10.1210/jc.2018-01320. doi: 10.1210/jc.2018-01320 pmid: 30239805
[36]	Kaing A, Jaswa EA, Diamond MP, et al. Highly elevated level of antimüllerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction[J]. Fertil Steril, 2021, 115(2):438-446. doi: 10.1016/j.fertnstert.2020.06.015. doi: 10.1016/j.fertnstert.2020.06.015 pmid: 32883514